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Background: Familial hyperaldosteronism type I (FH-I) is caused by the unequal recombination between the
11beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes, resulting in the generation of a CYP11B1/
B2 chimeric gene and abnormal adrenal aldosterone production. Affected patients usually show severe
hypertension and an elevated frequency of stroke at a young age. Aldosterone levels rise during pregnancy, yet in
pregnant women with FH-1, their hypertensive condition either remains unchanged or may even improve. The
purpose of this study was to investigate in vitro whether female sex steroids modulate the activity of chimeric
(ASCE) or wild type (ASWT) aldosterone synthase enzymes.
Methods: We designed an in vitro assay using HEK-293 cell line transiently transfected with vectors containing the
full ASCE or ASWT cDNAs. Progesterone or estradiol effects on AS enzyme activities were evaluated in transfected
cells incubated with deoxycorticosterone (DOC) alone or DOC plus increasing doses of these steroids.
Results: In our in vitro model, both enzymes showed similar apparent kinetic parameters (Km = 1.191 microM and
Vmax = 27.08 microM/24 h for ASCE and Km = 1.163 microM and Vmax = 36.98 microM/24 h for ASWT; p = ns,
Mann–Whitney test). Progesterone inhibited aldosterone production by ASCE- and ASWT-transfected cells, while
estradiol demonstrated no effect. Progesterone acted as a competitive inhibitor for both enzymes. Molecular
modelling studies and binding affinity estimations indicate that progesterone might bind to the substrate site in
both ASCE and ASWT, supporting the idea that this steroid could regulate these enzymatic activities and contribute
to the decay of aldosterone synthase activity in chimeric gene-positive patients.
Conclusions: Our results show an inhibitory action of progesterone in the aldosterone synthesis by chimeric or
wild type aldosterone synthase enzymes. This is a novel regulatory mechanism of progesterone action, which could
be involved in protecting pregnant women with FH-1 against hypertension. In vitro, both enzymes showed
comparable kinetic parameters, but ASWT was more strongly inhibited than ASCE. This study implicates a new role
for progesterone in the regulation of aldosterone levels that could contribute, along with other factors, to the
maintenance of an adequate aldosterone-progesterone balance in pregnancy.
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Primary aldosteronism is the most common form of
secondary hypertension, with an estimated prevalence
of 10% in referred patients and 4% in primary care [1,2]
but as high as 20% in patients with resistant hyperten-
sion [3,4]. Primary aldosteronism is characterised by
hypertension with low plasma renin activity and elevated
aldosterone levels that are often observed with hypo-
kalemia and abnormal adrenal steroid production [5].
Familial hyperaldosteronism type I (FH-I) occurs by an
unequal crossing-over of the genes encoding steroid
11β-hydroxylase (CYP11B1) and aldosterone synthase
(CYP11B2), resulting in a chimeric CYP11B1/B2 gene
that produces an enzyme with aldosterone synthase
activity with ectopic expression in the zona fasciculata,
which is regulated by plasma adrenocorticotrophic hor-
mone (ACTH) levels instead of by angiotensin II [6-8]. As
a consequence, aldosterone, 18-hydroxycortisol (18OHF),
and 18-oxocortisol (18oxoF) are produced. Different FH-I
pedigrees exhibit different crossover points between in-
tron 2 and exon 4, suggesting that the mutations arise
independently in each pedigree [9-11]. Exons 5 and 6 of
CYP11B2 are required for aldosterone, 18OHF, and
18oxoF production [12,13].
There is limited information about pregnancy in FH-1
women. It is a known fact that normal pregnancy is
characterised by an increase in maternal plasma volume
which is mediated, at least in part, by the activation of
the maternal renin-angiotensin system with increased
levels of renin activity, angiotensin II and aldosterone.
Furthermore, Gennari-Moser et al. recently demon-
strated that vascular endothelial growth factor (VEGF)
stimulates aldosterone synthesis in H295R adrenal cells
as assessed by the conversion of 3H-deoxycorticosterone
(DOC) to 3H-aldosterone. This novel mechanism may
also be operating during gestation [14]. During the first
trimester of pregnancy, aldosterone has a proliferative
effect on trophoblast in addition to causing a volume
expansion to allow the foetus to develop [15]. On the
other hand, progesterone has pleiotropic actions; for
instance, it can increase the synthesis of aldosterone
because is a substrate for 21-hydroxylase [16] and also
increase the mRNA levels of CYP11B2 in rats [17].
Progesterone also has an antagonist effect because it
competes with aldosterone by binding to the mineralo-
corticoid receptor (MR) [18]. Some authors have spec-
ulated that MR activation by DOC may be prevented
by a pre-receptor protective mechanism under normal
circumstances, although its nature is unclear [14,19].
Our findings suggest that there may be a close relation-
ship between the levels of these steroids, which must
be carefully regulated throughout pregnancy to prevent
hypertension, and reaching a successful delivery and a
healthy newborn.Because aldosterone, progesterone and estradiol in-
creased several fold during gestation but FH-1 pregnant
women did not experience a worsened hypertensive
condition, we hypothesised that sexual steroids might
modulate the activity of the chimeric and wild type
aldosterone synthase enzymes. Accordingly, we investi-
gated this hypothesis using an in vitro system.
The aims of this study were: a) to carry out an in vitro
assay to evaluate the activity of these enzymes using
HEK-293 cells line transfected with chimeric and wild type
aldosterone synthase enzymes, b) to investigate whether
progesterone and estradiol inhibits chimeric and wild type
aldosterone synthase enzymes in our in vitro assay, and c)
to examine the putative binding mode of these steroids to
chimeric and wild type aldosterone synthase enzymes by
molecular modelling studies.
Methods
Synthesis of the chimeric CYP11B1/B2 gene
Recently, we reported the unequal crossover break point
in the CYP11B1/B2 gene [20]. The 50-bp crossover re-
gion contains segments of intron 3 of CYP11B1 (c.2937-
40) and exon 4 of CYP11B2 (c.2937 + 10). Using the
PCMV-CYP11B1 and PCMV-CYP11B2 vectors and
based on restriction enzyme analysis, we selected a
crossover point to create the fusion vector containing
exons 1 to 3 of CYP11B1 (1-573 bp) and exon 4 to 9 of
CYP11B2 (574-1512 bp). Exons 5 and 6 of CYP11B2
were maintained in the chimeric enzyme. PCMV-
CYP11B1 and PCMV-CYP11B2 vectors were kindly pro-
vided by Dr. Walter L. Miller (University of California,
San Francisco). Mutagenex Inc. (Hillsborough, NJ, USA)
[21] performed the chimeragenesis of the CYP11B1/B2
gene. Restriction endonuclease digestion and Sanger se-
quencing confirmed the integrity of the plasmid con-
structs, and the amplification products were verified by
sequencing at Macrogen (Rockvill, MD, USA) [22].
Cell culture and transient transfections
The human embryonic kidney cell line, HEK-293, was
grown in high-glucose Dulbecco’s modified Eagle’s medium
(DMEM HG, Life Technologies, Sao Paulo, Brazil) sup-
plemented with 10% foetal bovine serum (FBS, Life Tech-
nologies, Sao Paulo, Brazil), 100 IU/mL penicillin and
100 μg/mL streptomycin. For the enzyme activity studies,
DMEM HG-FBS medium was treated with activated char-
coal to eliminate steroid contaminants. For the transfection
experiments, HEK-293 cells were plated at 6×105 cells per
well in 6-well plates and then transfected using Turbofect™
in vitro transfection reagent (Fermentas, Thermo Scientific,
Rockford, IL, USA), in accordance with the manufacturer's
protocol. Briefly, 2 μg of pCMV4, pCMV4-CYP11B1,
pCMV4-CYP11B2, or pCMV4-CYP11B1/B2 plasmid were
added in DMEM. pZsGreen1-n1 (0.3 μg, Clontech,
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ficiency. The transfected cells were visualised using a
Panasonic–DMC-LC40 LUMIX and the Pro-QV7software.
The efficiency of transfection was evaluated using an
Olympus CKX41 inverted microscope coupled to an
Olympus U-RFL-T. For this purpose, we took six photo-
graphs (40×) of plates containing HEK-293 cells (in each
condition) under bright field and again with the same field
of view under fluorescent light using a Micropublisher
3.3RTV camera and the Pro-QV7software. Then, the total
number of cells was counted under both conditions using
the Image J v1.46 program [18] in three independent trials.
Sodium dodecylsulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting
The whole-cell extracts of untransfected HEK-293,
PCMV-CYP11B1, PCMV-CYP11B1/B2 or PCMV-CYP
11B2-transfected cells were obtained using 100 μL of
lysis buffer containing protease inhibitors. The protein
concentration was estimated using the BCA protein col-
orimetric assay kit (Thermo Scientific, Rockford, IL,
USA) on an Infinite® 200 PRO NanoQuantmultimode
reader (Tecan, Männedorf, Switzerland). The denatured
protein samples (50 μg per well) were separated by 12%
SDS-PAGE and were immobilised onto 0.45-μm-pore
nitrocellulose membranes (Thermo Scientific, Rockford, IL,
USA). The membranes were probed with a rabbit anti-
human CYP11B2 antibody (aa 80–90 (RYNLGGPRMVC of
CYP11B2) followed by a goat anti-rabbit peroxidase-
conjugated antibody (Thermo Scientific, Rockford, IL,
USA), as previously described [23]. The CYP11B2 protein
was visualised using the enhanced chemiluminescence
Super Signal Pico Chemiluminescent Substrate kit (Thermo
Scientific, Rockford, IL, USA) and Agfa X-ray film (Agfa-
Gevaert, N.V, Mortsel, Belgium). Protein extracts from a
sample of human adrenal gland tissue were used as positive
control. The loading control was β-actin. The CYP11B1/B2
has an amino acid sequence of 1–191 from the N-terminus
of the CYP11B1 enzyme and was thus not detected by
this antibody.
Expression of CYP11B1/B2 and CYP11B2
Expression of CYP11B2 and CYP11B1/B2 in transfected
HEK-293 cells were evaluated by qRT-PCR. Total RNA
was extracted from transfected HEK-293 cells treated or
not with progesterone by TRIZOL® (Life Technologies,
California, USA) then reverse transcribed using RevertAid
H Minus Reverse Transcriptase (Thermo Scientific,
California, USA) following the manufacture’s instruc-
tion. Quantitative real-time polymerase chain reaction
was performed using Maxima SYBR (Thermo Scientific,
California, USA). Primers were CYP11B2 forward: 5`-
gga act tcc acc acg tgc cct tt-3` and CYP11B2 reverse:
5`- att gag gcc tgg cac gtc cc-3. GAPDH forward: 5-gaacat cat ccc tgc ctc tac t −3`, and GAPDH reverse: 5 –cct
gct tca cc acct tct tg −3. The mRNA expression was
quantified by ΔΔCt method relative to that of GAPDH
[24]. CYP11B2 primers are located in exons eight and
nine.Aldosterone synthase activity assay
To determine the kinetic constants under our assay con-
ditions, the PCMV-CYP11B1, PCMV-CYP11B1/B2, and
PCMV-CYP11B2 HEK-293 transfected cells at 18 h
post-transfection were incubated for 24 h with increas-
ing concentrations (ranging from 0.18 to 30 μmol/L) of
deoxycorticosterone as substrate (DOC, Steraloids Inc.,
Andover, MA, USA). Resultant aldosterone production
was quantified using HPLC-MS/MS (Agilent 1200, ABI
Sciex API4000 Qtrap). The apparent kinetics parameters
Km and Vmax were determined by plotting the aldoster-
one production versus the corresponding substrate con-
centrations and applying Michaelis–Menten kinetics using
the Prism v5.03 program (GraphPad Software, Inc.).Aldosterone synthase inhibitory assay
All chemicals were purchased from Sigma (Sigma-Aldrich
Quimica Ltda, Santiago, Chile). To determine any inhib-
ition by sex steroid hormones, at 18 h post-transfection
the cells were washed with PBS and 1.5 μmol/L DOC-
DMEM steroid hormone-depleted FBS and exposed to
24 hours of increasing concentrations of progesterone or
estradiol (0.625-10.0 μM). Ketoconazole (ranging from
0.625 to 5 μM) was used as an inhibitor control. The
supernatant (1.0 mL) was collected, and aldosterone levels
were measured by HPLC-MS/MS in four independent tri-
als. The IC50 was determined by plotting the aldosterone
production versus the corresponding log inhibitor concen-
trations and applying a dose–response inhibition analysis.Effect of progesterone on chimeric and wild type
aldosterone synthase activity
To determine the effect of progesterone on apparent
kinetic constants under our assay conditions, the PCMV-
CYP11B1/B2, and PCMV-CYP11B2 HEK-293 transfected
cells, after 18 h post-transfection, were incubated for 24 h
with increasing concentrations (ranging from 0.18 to
30 μM) of DOC (Steraloids Inc., Andover, MA, USA) and
progesterone at the IC50 concentrations for each enzyme.
The resultant aldosterone production in the supernatant
was quantified using HPLC-MS/MS (Agilent 1200, ABI
Sciex API4000 Qtrap). The apparent kinetics parameters
Km and Vmax were determined by plotting the aldoster-
one production versus the corresponding substrate con-
centrations and applying Michaelis–Menten kinetics using
the Prism v5.03 program (GraphPad Software, Inc.).
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The CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega) kit containing the tetrazolium compound
MTS ([3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt]) was used to
monitor cell viability according to the manufacturer’s pro-
tocols. Briefly, human embryonic kidney (HEK-293) cells
maintained in DMEM with 10% foetal bovine serum (FBS)
under standard cell culture conditions (37°C, humidified,
5% CO2) were plated at a density of 1.5×104 cells/well in a
96-well plate and incubated in growth media for 18 hours.
Cells were treated with 0.8 to-50 μM of progesterone,
estradiol or DOC in DMEM containing 10% FBS for
24 hours. After the indicated time of incubation with the
appropriate medium, a 20 μL MTS/PMS (1:0.05) mixture
was added per well, and cells were incubated for an add-
itional hour. MTS is reduced by viable cells to formazan,
which was monitored at 490 nm by an ELX-800 universal
plate reader (BioTek, Winooski, VT). Formazan produc-
tion is time dependent and proportional to the number of
viable cells. Cells not incubated in DMEM were used as
control condition. The percentage of cell death was calcu-
lated by the ratio of the optical density obtained in each
treatment to that obtained for the controls. A cytotoxic
concentration was noted when the optical density in each
condition was less than the average of the control minus
two standard deviations.
Molecular modelling of CYP11B1 and CYP11B1/B2
chimeric proteins and steroids docking
The amino acid sequence of the human CYP11B1 was
retrieved from the Uniprot database (entry code P15538),
and the chimeric CYP11B1/B2 sequence was obtained by
performing DNA sequencing [25]. The comparative mod-
elling was performed using the MODELLER program
implemented in the Build Homology Models protocol in
Discovery Studio v2.1 (Accelrys Inc., San Diego, USA)
[26] using the recently reported crystal structure of hu-
man CYP11B2 in complex with DOC, which was identi-
fied as a suitable template for the modelling of both
proteins (PDB id 4DVQ, resolution 2.49 Å) [27]. For mod-
elling purposes, the first 33 residues of each protein were
not included. The coordinates for DOC and the HEME
group were modelled using the copy ligand parameter
from the template structure, from which the Chain A
was used. One hundred models for each protein were
generated, and the top ranked by the MODELLER
internal DOPE score energy minimized using the con-
jugate gradient algorithm until a RMS gradient of
0.001 kcal/mol Å was reached. The CHARMM22 force
field with a dielectric constant of 4 and a distance-
dependent dielectric implicit solvent model was used to
mimic the membrane environment [28]. Model quality
was assessed by Ramachandran plot analysis, PROSAand Verify3D structure validation [29-31]. The electro-
static potential energy profiles were calculated using
APBS [32]. Conformers of each docked compound were
obtained with OMEGA v2.4.6 using default parameters
[33,34]. Docking calculations were performed using
FRED v3.0 (OpenEye Scientific Software, Santa Fe, New
Mexico) [35], and the solutions ranked according to the
Chemgauss4 scoring function [36].
Data analysis
Data are expressed as the mean +/- SEM. The kinetic
parameters Vmax and Km were obtained by Prism v5.03.
Differences between the means were analysed by repeated
measures of an ANOVA and Tukey’s post hoc test. Differ-
ences of area under curve analyses were performed by the
Mann Whitney test. Statistical analysis was performed
using Prism v5.03 (GraphPad Software, Inc.). Differences
were considered significant at p < 0.05.
Results
Design of vectors and chimeragenesis
As described in the methods section, the crossover point
was used in the chimeragenesis to create the fusion
vector CYP11B1 (1-573 bp)/CYP11B2 (574-1512 bp). A
schematic representation of the FH-I crossover and the
resultant ASCE product that was synthesised for assay
studies is shown in Figure 1A.
In vitro expressed ASCE displayed similar aldosterone
production to ASWT
A representative image of HEK-293 transfected with
wild type or chimeric expression vectors are shown in
Figure 1B. Morphological changes were not observed
between the HEK-293 cells transfected with the constructs
containing the CYP11B enzymes and the cells transfected
with the PCMV vector or the non-transfected cells (NT).
Comparable transfection efficiencies were observed by
counting cells that express the green fluorescent protein,
which correlated with the total number of cells for each
assay condition (Figure 1C). The expression of the aldos-
terone synthase in HEK-293 cells transfected with the
constructs containing the CYP11B2 was examined by
Western blotting (Figure 1D). A human adenoma sam-
ple from the adrenal cortex was used as positive control
(line 1), and the following were observed: no transfected
HEK-293 (line 2); PCMV-CYP11B1 (line 3); PCMV-
CYP11B1/B2 (line 4) and PCMV-CYP11B2 (line 5). An
intense immunoreactive band with an apparent molecu-
lar weight of approximately 50 kDa was present in the
human adenoma sample and in the HEK-293 cells
transfected with PCMV-CYP11B2. Western blotting using
a CYP11B1 antibody was performed for the same samples.
Unfortunately, the immunoreactivity band was too weak.
To probe the CYP11B1 activity of PCMV-CYP11B1
Figure 1 Expression of aldosterone production by ASCE and ASWT in vitro. A) Schematic representation of the CYP11B1/B2 chimeric gene,
showing the crossover region between intron 3 of CYP11B1 and exon 4 of CYP11B2. B) A representative image of the transfection efficiency.
Green fluorescence (upper panel) and the same bright field (lower panel) of transfected or non-transfected HEK-293 (NT). C) An average
transfection efficiency of 50 percent was observed from three independent experiments for each construct. D) A representative Western blot of
CYP11B2. Line 1, human adrenocortical adenoma; line 2, NT-HEK-293; line3, PCMV-CYP11B1 transfected HEK-293; line 4, PCMV-CYP11B1/B2; and
line 5, PCMV-CYP11B2 transfected HEK-293. Actin was used as a loading control.
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HEK-293 cells with increasing concentrations of cortico-
sterone (0.6-1.5 μM), and we obtained the expected in-
creasing levels of cortisol (data not shown).
ASCE and ASWT displayed similar calculated kinetics
enzymatic parameters in vitro
The transfected HEK-293 cells supported CYP11B2- and
CYP11B1/B2-dependent steroid conversion without the
additional heterologous expression of the corresponding
electron donor system, similar to previous experiments
reported by Denner et al. [37]. Figure 2A shows a dose
response curve performed for five independent HEK-293
transfections of PCMV-CYP11B1/B2, PCMV-CYP11B2
or PCMV-CYP11B1 (11β-hydroxylase gene, 11BH), in-
cubated with increasing concentrations of DOC (0.18-
30 μM) for 24 hours. The aldosterone production versus
substrate concentration was plotted for ASCE (open
circles), ASWT (closed circles) and 11BH (grey circles).11β-hydroxylase did not produce aldosterone in any of
the DOC concentrations that were probed. The apparent
kinetic enzyme parameters obtained were Km= 1.191 μM
and Vmax = 27.08 μM/24 h for ASCE and Km= 1.163 μM
and Vmax = 36.98. The comparison of the area under the
curve for aldosterone production by ASCE and ASWT did
not show any significant differences (p = 0.3095 Mann–
Whitney test). This finding suggests that both enzymes
exhibited analogous affinity for the substrate and showed
the same efficiency to produce aldosterone. DOC did
not exhibit a toxic effect at any concentration probed
(Figure 2B). Non-transfected HEK-293 cells incubated
with DOC (1.5 μM) did not produce aldosterone (data
not shown).
Aldosterone production by ASCE and ASWT was inhibited
by progesterone but not by estradiol
The average aldosterone production by ASCE was
13.6 μM/24 h and by ASWT was 15 μM/24 h when the
Figure 2 Enzyme kinetics of aldosterone production by ASCE
and ASWT in vitro. A) Dose response curves of aldosterone
production catalysed by ASCE (open circles), ASWT (closed circles) and
11β-hydroxylase (grey circles) incubated with 11-deoxycorticosterone
(DOC 0.18-30 μM) for 24 h. Data are expressed as the mean +/− S.E.M.
of 5 independent trials. The apparent kinetic enzyme parameters
obtained were Km= 1.191 μM and Vmax = 27.08 μM/24 h for ASCE and
Km= 1.163 μM and Vmax = 36.98 μM/24 h for ASWT, and the area under
curve for each of the enzyme activities (ANOVA and Mann–Whitney test,
p = 0.3095) is shown within the graph. B) Cell viability of HEK-293
incubated with increasing doses of DOC (0.8-50 μM).
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presence of DOC as substrate, progesterone inhibited
the aldosterone production by both ASCE and ASWT in
a dose-dependent manner with similar efficacies. Statisti-
cally significant inhibition of ASCE was achieved at
5 μM of progesterone (Figure 3A, white bars), and statis-
tically significant inhibition of ASWT was achieved at
2.5 μM of progesterone (Figure 3A, black bars). For
ASCE, the calculated IC50 value for progesterone was
3.907 μM, and for ASWT, it was 2.240 μM (Figure 3B).
These inhibition values were not due to an inhibition in
plasmid transcription efficiency (See Additional file 1:
Figure S1). Estradiol did not affect ASCE or ASWT aldos-
terone synthase activity in the range of concentrations
assayed (Figure 3C) or coincubated with progesterone
(See Additional file 2: Figure S2). As expected, the known
aldosterone synthase inhibitor ketoconazole inhibited both
enzyme activities by 90% at all concentrations probed
(Figure 3D). None of the steroids assayed nor ketocona-
zole demonstrated cytotoxic effects in HEK-293 cells in
any of the concentrations that were probed (Figure 3E).
As a control, non-transfected HEK-293 cells were treatedwith the same increasing concentrations of progesterone
or estradiol. No aldosterone production was detected
under these conditions (data not shown). The vectors
PCMV-CYP11B2 or PCMV-CYP11B1/B2 used in the
transfection experiments with HEK-293 cells have the
same viral promoter. For that reason, the expression levels
of chimeric or wild type aldosterone synthase should be af-
fected by the same effectors. Data in Figure 3 are expressed
as the mean +/− S.E.M. of four independent trials.
Molecular modelling of CYP11B1 and ASCE proteins
We developed 3D models of both proteins by compara-
tive modelling using the human CYP11B2 (ASWT) crys-
tal structure. In the final alignment used to model the
proteins, the percentage of sequence identity was 93.6%
and 97.7% for the modelled region, and 96.4% and 98.9%
homologies were observed between the template struc-
ture and CYP11B1 and ASCE, respectively. For ASCE,
the grey bar indicates the corresponding CYP11B1 por-
tion, and the green bar represents the CYP11B2 limits for
ASCE (See Additional file 3: Figure S3). A Ramachandran
plot analysis indicated that the modelled proteins have
more than 95% of the residues in the allowed region. The
PROSA Z-scores and Verify3D profile scores also support
the quality of the obtained models for further studies
(Table 1). The obtained models exhibit a root-mean square
deviation (RMSD) of alpha carbons of less than 0.4 Å
when superimposed on the template structure. Figure 4
depicts the secondary structure of the modelled proteins
compared to ASWT. The ASCE model (Figure 4B) is
composed of the first 38% of the 11BH (residues 34 to
191), which contains the substrate (steroid) entry region of
CYP11B1, and the last 62% of the ASWT (residues 192–
503). All models have the common folding pattern of
CYP450 enzymes, and according to the identified cross-
over, the shift will occur at the end of helix G. Electrostatic
potential surface profiles of the proteins indicate that the
surface potential of ASCE is more similar to that of
ASWT, with the steroid binding site access channel in
ASCE being more electronegative and more extended
than that of ASWT, as determined by the size of the asso-
ciated cavities, which are 471.87 and 553.62 Å3 for ASCE
and ASWT, respectively (Table 2).
Type of inhibition and docking of steroids to CYP11B1,
ASCE and ASWT proteins
To gain insight into the inhibition profile of progesterone,
we performed kinetic experiments in the presence of the
corresponding IC50 concentrations of progesterone for
each enzyme (Figures 5A and 5D). In progesterone pres-
ence, ASCE Km was very variable and lightly increase,
Vmax was no statistically different (p = 0.0667). ASWT
Km significantly increase (p = 0.0095) but Vmax was no
statistically different (p = 0.1048). The new calculated
Figure 3 Dose response effect of steroids on DOC-incubated release of aldosterone by PCMV-CYP11B2- or chimeric PCMV-CYP11B1/B2-
transfected HEK-293 cells. The mean aldosterone production by ASCE was 13.6 μM/24 h and by ASWT was 15 μM/24 h, when incubated with
1.5 μM of DOC. A) Inhibition of ASCE by progesterone was statistically significant from 5 μM and for ASWT from 2.5 μM (+ and *, p > 0.01).
B) Dose response curve for aldosterone production by ASCE and ASWT (μM/24 h) versus the logarithm of the progesterone concentration. A
calculated IC50 value of 3.907 μM for ASCE and 2.240 μM for ASWT was obtained. C) Estradiol shows no inhibitory activity on the ASCE or ASWT
enzymes in the range of concentrations probed. D) Ketoconazole inhibited both enzymes by 90% at all concentrations probed (p < 0.001). E) Cell
viability of HEK-293 incubated with increasing doses of progesterone and estradiol (progesterone and estradiol or ketoconazole) (0.8-50 μM). Data
are expressed as the mean +/− S.E.M. of 4 independent trials.











Favoured Allowed Outlier Verify score Max verify score Min verify score
CYP11B2 NA 0.00 99.6 0.2 0.2 204.69 214.638 96.58 −9.50 471.87
CYP11B1 −58932.24 0.24 96.6 0.2 0.2 196.41 214.178 96.38 −9.97 515.12
CYP11B1/B2 −58732.37 0.32 97.2 1.5 1.3 195.07 214.178 96.38 −10.13 553.62
a: RMSD (root-mean square deviation) from Template CYP11B2 (PDB id 4DVQ, Chain A).
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Figure 4 Molecular modelling of CYP11B1 and ASCE proteins. Schematic representation of the secondary structures and electrostatic
potential profiles of CYP11B1 (11BH, Panel A), CYP11B1/B2 (ASCE, Panel B) and CYP11B2 (ASWT, Panel C). The ASCE secondary structure is colored
according to crossover occurring at helix G, where grey represents the CYP11B1 portion and green represents the CYP11B2 portion of the
chimeric enzyme. The solvent accessible surface colored according to the calculated electrostatic potential shows that the steroid binding site in
ASCE is more electronegative and more extended than that of the ASWT (553.62 v/s 471.87 Å3).
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gesterone were Km = 2.451 μM and Vmax = 37.91 μM/
24 h for ASCE, and Km = 10.78 μM and Vmax =
51.61 μM/24 h for ASWT. Progesterone inhibits the al-
dosterone synthase wilde type in a competitive fashion.
To explore the putative binding mode of the steroid
compounds in CYP11B1, ASCE and ASWT, we performed
docking simulations within the binding site of all proteins.
Figure 5B and C show the most favourable predicted bind-
ing mode obtained for DOC and progesterone within the
ASCE, where progesterone binds with its 3-carboxy group
facing the inner part of the binding pocket that is com-
posed of the side chains of Arg120 and Glu310. The com-
position of this binding pocket is similar to that of DOC in
ASCE and ASWT (Figure 5B and E, respectively), but pro-
gesterone penetrates deeper into the pocket with stabilisa-
tion via a hydrogen bond interaction with Arg120. TheTable 2 Summarised docking results
Ligand CYP11B2





ΔGbind: Calculated as Ludi2 Score /-73.33 (kcal/mol).methyl groups at positions 18 and 19 face the HEME
group and are surrounded by the side chains of Ala313
and Thr318. The beta side of the steroid scaffold faces the
top of the aromatic cluster pocket composed by Trp116,
Trp260, Phe231 and Phe487. Figure 5F represents the most
favourable predicted binding mode obtained for progester-
one with ASWT.
DOC and progesterone have a similar binding mode in
CYP11B1 as that predicted for ASCE (See Additional file 4:
Figure S4A and Figure S4B) and as the experimentally
determined binding mode of DOC to ASWT (Figure 5B).
Estradiol binds with its aromatic portion positioned
inside the pocket and interacts with the pocket via its
aromatic portion with the side chains of Phe130, Trp116
and Trp260 but fails to establish any H-bond interac-
tions with the binding site (See Additional file 4: Figure
S4C). Finally, ketoconazole binds with its imidazoleCYP11B1/B2





Figure 5 Type of inhibition and docking of steroids to ASCE and ASWT proteins. The new calculated kinetic enzyme parameters obtained
in the presence of the corresponding IC50 concentration of progesterone for each enzyme were Km = 2.451 μM and Vmax = 37.91 μM/24 h for
ASCE, and Km = 10.78 μM and Vmax = 51.61 μM/24 h for ASWT. Progesterone inhibits the aldosterone synthase wild type in a competitive
fashion. (A and D). Docking experiments show that DOC binds in a similar mode to ASCE compared to ASWT (B and E). Progesterone also has a
similar binding mode to ASCE and ASWT, but penetrates deeper into the ASCE pocket (C and F).
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http://www.rbej.com/content/11/1/76moiety making direct contact with the iron atom in the
HEME group, with its dichlorophenyl group making
aromatic interactions with Phe130 and Trp116, and with
its terminal amide in making H-bond interactions with
Asn404 (See Additional file 4: Figure S4D). The binding
energies displayed in Table 2 suggest that sex steroids
can bind to both proteins, ASCE and ASWT, but with
lower affinity than ketoconazole or DOC to ASWT,
according to the ChemGauss4 scoring and Ludi2 scoring
function-derived binding energies.
Discussion
In this work, we demonstrated for the first time that
progesterone inhibits ASCE and ASWT but that estra-
diol had no effect in our system. To probe this, we suc-
cessfully generated an in vitro system expressing ASCE
and ASWT in transfected HEK-293 cells. Moreover, in
our in vitro model, we assumed that both enzymes were
expressed in similar amounts because the percent of
cells transfected was similar when using different vec-
tors. In vitro aldosterone production following increasing
DOC concentration was reproducible and comparable in
independent trials for both enzymes, with similar Vmax
and Km. Progesterone inhibited the ASCE with lower
potency than but similar efficacy as ASWT. This is a
novel result because previous reports have demonstrated
that progesterone reduces the blood pressure via an
antagonising effect on mineralocorticoid receptors and
peripheral vasorelaxation [38-40].We found that progesterone inhibited both ASCE and
ASWT, which is in agreement with studies from the
Marquet group that showed that progesterone deriva-
tives inhibit ASWT activity [41,42]. However, these find-
ings are in contrast to published studies on animal
models, where progesterone increased aldosterone pro-
duction by ASWT [17] and increased mRNA CYP11B2
production [17]. In our system, estradiol showed no ef-
fect on both ASCE and ASWT activities in contrast to
the results reported by Kau, where an increase in the
production of aldosterone by estradiol replacement in
ovariectomised rat was shown [43].
Modelling studies support the competitive inhibitory
effect of progesterone observed in vitro, which shows
that DOC, the natural substrate, and progesterone have
a similar binding mode within the active site of both en-
zymes. DOC and progesterone interact with the same
amino acids of the active site on ASCE and ASWT,
which is in agreement with the aldosterone production
obtained by both enzymes in vitro. However, the model-
ling analysis showed that the steroid entrance loop in
ASCE corresponds to CYP11B1, which is different from
ASWT. Interestingly, a feature of ASCE is that it contains
all of the substitutions reported to convert CYP11B1 into
an aldosterone synthase enzyme, such as S288G, V320A
and N335D [12,44]. The docking simulations also support
that non-aromatic sex steroids, such as progesterone,
possessing a structure similar to the endogenous substrate,
bind to the steroid binding pocket with higher affinity
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http://www.rbej.com/content/11/1/76than aromatic sex steroids, such as estradiol. Conform-
ational flexibility is an important feature for substrate spe-
cificity and for the positioning of substrates within the
binding pocket for further enzymatic processing; there-
fore, the planar aromatic ring of estradiol will reduce its
conformational flexibility and binding to the steroid cavity
in ASCE and ASWT.
According to our in vitro and in silico results, we
would expect that the plasma aldosterone concentration
should decrease as progesterone levels increase along-
side gestation. On the contrary, it is generally accepted
that, in pregnancy, plasma aldosterone and progesterone
concentrations increase. How does one solve this discrep-
ancy? Some authors have speculated that the mineralocor-
ticoid receptor (MR), under normal circumstances, may
be protected from activation by DOC via a pre-receptor
protective mechanism, although the nature of which is un-
clear. We believe that during gestation there is a close re-
lationship between aldosterone and progesterone levels,
which must be carefully regulated alongside pregnancy to
prevent the onset of hypertension and to have a successful
delivery and a healthy newborn. We postulated that pro-
gesterone may have a multifactorial role on aldosterone
production: on one hand, it would favour aldosterone syn-
thesis by acting as a substrate for adrenal 21-hydroxylase
[16] or by increasing the expression of CYP11B2 mRNA
levels [17], and on the other hand, it would inhibit aldos-
terone synthase activity, thereby protecting the mother
not only from the systemic effects of aldosterone produc-
tion but also from the devastating local effects of aldoster-
one production.
Conclusions
In summary, we have determined the kinetic parameters
for ASCE and ASWT in our in vitro model, and we have
demonstrated that progesterone but not estradiol inhibited
the aldosterone synthase activity of ASCE and ASWT
in vitro. This finding suggests a novel pre-receptor mech-
anism of control for aldosterone levels by progesterone,
differing from the previously described mechanisms, such
as binding to the mineralocorticoid receptor. This mech-
anism may operate as a buffering system in pregnant
women where high levels of progesterone are produced by
the placenta, suggesting that this mechanism could be im-
portant in preventing the deleterious effects of aldosterone
on vasculature.
Additional files
Additional file 1: Figure S1. Quantitive RT-PCR of No transfected (NT)
or CYP11B2 or CYP11B1/B2 transfected HEK-293 cell and incubated with
different progesterone concentration (0.625 to 5 μM). There were no
differences in mRNA expression by progesterone respect to each control
condition (without progesterone).Additional file 2: Figure S2. CYP11B2 or CYP11B1/B2 transfected HEK-
293 cell were incubated with different combination of estradiol/
progesterone concentration. Different dose response for aldosterone
production by ASCE (A) and ASWT (B) (μM/24 h). Estradiol had no
additional inhibitory effect on wild type or chimeric aldosterone synthase
activity when was co-incubated with progesterone.
Additional file 3: Figure S3. Sequence alignment used to model
proteins CYP11B1/B2 (ASCE) and CYP11B1 using human CYP11B2 (ASWT)
as template. The percentage of sequence identity was 93.6% and 97.7%
for the modelled region, and 96.4% and 98.9% homologies were
observed between the template structure and CYP11B1 and ASCE,
respectively. For ASCE, the grey bar indicates the corresponding CYP11B1
portion, and the green bar represents the CYP11B2 limits for ASCE.
Additional file 4: Figure S4. The 11OH-deoxycorticosterone (DOC) and
progesterone predicted binding mode to CYP11B1 (A and B,
respectively). Estradiol binding mode to ASCE (C) and ketoconazole
binding to ASWT binding pocket (D).
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